No Data
No Data
CICC: Maintains an outperform rating on Chinares Pharma with a target price of HKD 7.3.
CICC released a research report stating that Chinares Pharma (03320) was maintaining its rating of "outperform the industry," with EPS forecasts of $0.69/$0.77 for 2024/2025 remaining unchanged, corresponding to a year-on-year increase of 12.0%/12.2%, with a target price of HK$7.3. On July 17th, the company announced that its subsidiary, China Resources Boya Bio-Pharmaceutical Group, intends to acquire 100% equity of Lvxing Hong Kong Holdings for 1.82 billion yuan. On July 11th, Dong-E-E-Jiao, a subsidiary of the company, released its performance forecast for the first half of 2024, with preliminary estimates of net income attributable to shareholders at 0.695-0.76 billion yuan, a year-on-year increase of 31-43%. CICC's main points of view are as follows:
Is KPC PharmaceuticalsInc (SHSE:600422) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know
Private Companies Among KPC Pharmaceuticals,Inc's (SHSE:600422) Largest Stockholders and Were Hit After Last Week's 7.7% Price Drop
Key Insights Significant control over KPC PharmaceuticalsInc by private companies implies that the general public has more power to influence management and governance-related decisions A total of 1
chinare pharma (03320.HK): KPC Pharmaceuticals, Inc. intends to acquire a 51% stake in Huaren Shenghuo for 1.791 billion yuan.
On June 11th, Glonhui reported that CR Pharma (03320.HK) announced that on June 7, 2024, the board of directors passed a resolution and approved the equity transfer agreement to be signed by CR Sanjiu (000999.SZ), a non-wholly owned subsidiary of the company, and Kunming Pharmaceutical Group (600422.SH) ("Equity Transfer Agreement"). Accordingly, CR Sanjiu will agree to sell and Kun Pharma will agree to acquire 51% equity interest of Kunming CR Sanjiu Medical & Pharmaceutical Co., Ltd. ("CR Sanjiu") for a total consideration of RMB 1.791 billion ("Proposed Internal Restructuring"). As of this announcement, CR Sanjiu is owned by CR.
China Resources Sanjiu Medical & Pharmaceutical (stock code: 000999.SZ) intends to transfer 51% equity of Huaren Shenghuo to KPC Pharmaceuticals, Inc.
On June 7th, Gelunhui reported that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) announced that it holds 100% equity of Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. (referred to as "China Resources Shenghuo"). In order to implement the company's "14th Five-Year Plan" strategic plan, optimize the layout of the industrial chain, promote the high-quality development of the 37 industrial chain, further enhance China Resources Sanjiu's influence in the 37 industry, and solve the problem of same-industry competition between China Resources Shenghuo and the company's controlling subsidiary Kunming KPC Pharmaceuticals, Inc. (referred to as "KPC Pharmaceuticals"), the company plans to sign an "Equity Transfer Agreement" with KPC Pharmaceuticals, intending to transfer 51% of the equity of China Resources Shenghuo to KPC Pharmaceuticals.
Express News | Kpc Pharmaceuticals Says It Plans to Buy 51% Stake in China Resources Sanjiu's Unit for 1.8 Bln Yuan
No Data